Published in J Transl Med on July 28, 2011
Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas. Cancer Gene Ther (2013) 0.84
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Expression of genes transferred into monocot and dicot plant cells by electroporation. Proc Natl Acad Sci U S A (1985) 12.21
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology (2010) 2.06
Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol (1988) 1.91
Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer (1993) 1.90
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
Stochastic model for electric field-induced membrane pores. Electroporation. Biophys Chem (1984) 1.84
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. J Natl Cancer Inst (1996) 1.74
Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68
Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg (2010) 1.64
Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res (1988) 1.57
Antisense therapy for cancer. Nat Rev Cancer (2005) 1.54
Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer (2008) 1.53
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 1.50
Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev (2000) 1.50
Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol (2010) 1.48
Monoclonal antibody production by receptor-mediated electrically induced cell fusion. Nature (1984) 1.42
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer (1996) 1.41
Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol (1991) 1.37
Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol (2009) 1.32
Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res (2000) 1.19
Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res (1999) 1.15
Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode. Breast Cancer Res Treat (2010) 1.14
Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res (2000) 1.11
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Electromobility of plasmid DNA in tumor tissues during electric field-mediated gene delivery. Gene Ther (2002) 1.07
Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer (1999) 1.05
Exploring new instrumentation parameters for electrochemotherapy. Attacking tumors with bursts of biphasic pulses instead of single pulses. IEEE Eng Med Biol Mag (1999) 1.01
Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res (2000) 1.00
Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res (2005) 0.99
Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol (2006) 0.98
Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J Exp Clin Cancer Res (2003) 0.97
Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma. Melanoma Res (2006) 0.95
Patterns of tumor response in canine and feline cancer patients treated with electrochemotherapy: preclinical data for the standardization of this treatment in pets and humans. J Transl Med (2007) 0.94
Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol (2002) 0.93
Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst (2000) 0.93
A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther (2000) 0.92
Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate (2007) 0.91
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.90
Electrochemotherapy of Mycosis fungoides by interferon-alpha. Bioelectrochemistry (2006) 0.89
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol (2005) 0.88
Rational design of new electrodes for electrochemotherapy. J Exp Clin Cancer Res (2005) 0.87
Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res (2007) 0.86
Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum Gene Ther (2002) 0.85
Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther (2001) 0.85
Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res (2005) 0.85
IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol (2008) 0.85
Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. In Vivo (2007) 0.84
Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther (1997) 0.83
Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res (2008) 0.82
Electrochemotherapy for localized lymphoma: a preliminary study in companion animals. J Exp Clin Cancer Res (2007) 0.82
G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther (2003) 0.80
High frequency fusion of plant protoplasts by electric fields. Planta (1981) 0.79
Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucleic Acid Drug Dev (1999) 0.79
Retracted Bleomycin/interleukin-12 electrochemogenetherapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther (2010) 0.78
Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev (1999) 0.77
Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature (2008) 4.28
Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 2.78
Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol (2003) 2.30
Widespread myocardial inflammation and infarct-related artery patency. Circulation (2004) 2.27
Retinal phenotypes in patients homozygous for the G1961E mutation in the ABCA4 gene. Invest Ophthalmol Vis Sci (2012) 2.26
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation (2008) 2.23
Identification of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res (2007) 2.08
Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane's retraction syndrome. Science (2008) 1.84
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle (2011) 1.80
Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation (2004) 1.73
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol (2007) 1.66
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther (2005) 1.65
c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell (2006) 1.64
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Myocardial infarction induces embryonic reprogramming of epicardial c-kit(+) cells: role of the pericardial fluid. J Mol Cell Cardiol (2009) 1.57
New evidence of the presence of endometriosis in the human fetus. Reprod Biomed Online (2010) 1.52
TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell (2010) 1.50
SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res (2012) 1.48
Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A (2005) 1.47
Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol (2002) 1.47
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J (2006) 1.42
MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. Cancer Biol Ther (2009) 1.42
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep (2009) 1.39
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest (2007) 1.39
Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell (2006) 1.38
Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer (2010) 1.38
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res (2003) 1.37
Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol (2004) 1.37
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol (2008) 1.36
Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol (2002) 1.34
Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol (2003) 1.34
Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol (2008) 1.33
Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res (2009) 1.29
Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol (2006) 1.26
HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets (2009) 1.25
Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol (2009) 1.23
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer (2007) 1.22
Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem (2003) 1.21
Electron microscopy characterization of cardiomyocyte apoptosis in ischemic heart disease. Int J Cardiol (2005) 1.19
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes (2006) 1.16
Conditions suggesting lymphoma: case 2. Mediastinal liposarcoma in a patient with previous testicular cancer. J Clin Oncol (2005) 1.15
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Cyclin T: three forms for different roles in physiological and pathological functions. J Cell Physiol (2003) 1.15
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes (2004) 1.15
Osteoblastoma of the jaw: report of two cases and review of the literature. In Vivo (2006) 1.13
Endometriosis: new concepts in the pathogenesis. Int J Biochem Cell Biol (2010) 1.13
TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol (2013) 1.12
Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol (2009) 1.12
IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol (2009) 1.11
MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem (2003) 1.10
Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol (2008) 1.10
Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS One (2010) 1.10
New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv (2011) 1.09
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 1.09
Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol (2006) 1.09
TLR3 essentially promotes protective class I-restricted memory CD8⁺ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood (2011) 1.09
CD4(+) T cell vaccination overcomes defective cross-presentation of fungal antigens in a mouse model of chronic granulomatous disease. J Clin Invest (2012) 1.07
Identification of protein disulfide isomerase as a cardiomyocyte survival factor in ischemic cardiomyopathy. J Am Coll Cardiol (2007) 1.07
Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol Immunol (2012) 1.05
Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One (2009) 1.05
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. Eur J Cancer (2006) 1.04
E1A deregulates the centrosome cycle in a Ran GTPase-dependent manner. Cancer Res (2003) 1.04
Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. J Biol Chem (2004) 1.04
Use of an electrothermal bipolar tissue sealing system in lung surgery. Eur J Cardiothorac Surg (2006) 1.03
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine (2011) 1.03
Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol Cancer (2010) 1.03
Pattern of expression of HtrA1 during mouse development. J Histochem Cytochem (2004) 1.02
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol (2007) 1.02
Identification of genes down-regulated during lung cancer progression: a cDNA array study. J Exp Clin Cancer Res (2008) 1.01
Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after an acute myocardial infarction. Circulation (2002) 1.00
Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol (2005) 0.99
Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. Am J Obstet Gynecol (2008) 0.99
Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med (2011) 0.99
Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol (2006) 0.98
Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol (2005) 0.97
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res (2008) 0.97
Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J (2005) 0.97